may edition file

More documents

Recommendations

Info

Surgery) can now go for MCh Surgical Oncology. Earlier the prior requirements were MS (Surgery), MS (ENT), MS (Orthopaedics), MD (Obst. & Gyn). Surgeons with MS (General Surgery) can apply for MCh (Head & Neck Surgery). Earlier they were MS (ENT) or MS (General Surgery) or MCh (Plastic & Reconstructive Surgery) or MCh (Surgical Oncology) or MCh (Neuro Surgery). Generic eribulin launched in India Ageneric version of the anticancer drug eribulin, which is currently marketed under the brand name Halaven by Eisai Pharmaceuticals, is now available in India. The generic eribulin will be 40% cheaper than Halavan, said Emcure Pharmaceuticals, which launched the cancer treatment. Eribulin, originally isolated halichondrin B from the natural Japanese marine sponge Halichondria okadai, was approved by the US FDA on November 15, 2010 for the treatment of metastatic breast cancer. Considered less toxic, eribulin is currently used as second-line treatment for relapsing triple-negative breast cancer. Triple-negative breast cancer is tough to treat as the patients with this sub-type are tested negative for all the three receptor proteins — oestrogen, progesterone as well as HER2. Eisai won the second approval from the US FDA for eribulin in January 2016 or the treatment of liposarcoma in patients who had undergone anthracycline-based chemotherapy. Presently, eribulin is being investigated for use in various cancers such as non-small cell lung cancer, prostate cancer and sarcoma. Measles cases shoot up globally: WHO Reported cases of measles rose by 300 per cent Stop Thal to prevent thalassemia Kanakia Health Care, Mumbai, has created a program called STOP THAL under the guidance of Dr Swati Kanakia, a paediatric haemato-oncologist with a PhD in Thalassemia from Mumbai University. STOP THAL, Screening for Thalassemia and Opting for PREVENTION, is aimed at preventing thalassemia major cases in an effort to reduce the disease burden. Dr Kanakia firmly believes that the only way to reduce thalassemia major cases is by prevention. However, how does one suspect thalassemia? The “Magic Mantra” for considering thalassemia minor is low or normal hemoglobin, high RBC count, microcytosis and a normal RDW. This is followed up by hemoglobin electrophoresis, which detects only beta thalassemia. If there is a strong suspicion of thalassemia despite a normal Hb electrophoresis, mutations for the alpha thalassemia gene <strong>may</strong> be carried out to clinch the diagnosis. Each and every doctor can play a pivotal role by considering thalassemia on a regular CBC report done for any reason. Dr Kanakia hopes that STOP THAL will prove to be useful in reducing thalassemia major cases. The program, available at http://kanakiahealthcare. com/stopthal/, helps one to estimate the chances of having a completely normal, thalassemia minor, or thalassemia major child. It will be an important asset to increase awareness amongst thalassemia patients, and doctors <strong>may</strong> use it as an aid for patient education. in the first three months of 2019 compared to the same period in 2018, shows preliminary global data by WHO. This follows consecutive increases over the past two years. Measles, a highly contagious airborne viral infection, can be entirely prevented through a twodose vaccine. But vaccination rates have been slipping in recent months. Global coverage with the first dose of measles vaccine has stalled at 85 percent for several years. This is still short of the 95 percent needed to prevent outbreaks, and leaves many people in many communities at risk. Second dose coverage, while increasing, stands at 67 percent. “While this data is provisional and not yet complete, it indicates a clear trend. Many countries are in the midst of sizeable measles outbreaks, with all regions of the world experiencing sustained rises in cases,” WHO said in a statement. Current outbreaks include the Democratic Republic of the Congo, Ethiopia, Georgia, Kazakhstan, Kyrgyzstan, Madagascar, Myanmar, Philippines, Sudan, Thailand and Ukraine, causing many deaths – mostly among young children. Over recent months, spikes in case numbers have also occurred in countries with high overall vaccination coverage, including the United States of America as well as Israel, Thailand, and Tunisia. The agency noted that only about one in 10 actual measles cases are reported, meaning the early trends for 2019 likely underestimate the severity of the outbreaks. 10 May 2019
Transvaginal mesh banned in US amid safety concerns The US Food and Drug Administration ordered the manufacturers of all remaining surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse (POP) to stop selling and distributing their products immediately. The order is the latest in a series of escalating safety actions related to protecting the health of the thousands of women each year who undergo surgery transvaginally to repair POP. The FDA has determined that the manufacturers, Boston Scientific and Coloplast, have not demonstrated a reasonable assurance of safety and effectiveness for these devices, which is the premarket review standard that now applies to them since the agency reclassified them in class III (high risk) in 2016. As part of the 2016 reclassification, manufacturers were required to submit and obtain approval of premarket approval (PMA) applications, the agency’s most stringent device review pathway, in order to continue marketing their devices in the US. “In order for these mesh devices to stay on the market, we determined that we needed evidence that they worked better than surgery without the use of mesh to repair POP. That evidence was lacking in these premarket applications, and we couldn’t assure women that these devices were safe and effective long term,” said Jeffrey Shuren, MD, director of the FDA’s Center for Devices and Radiological Health. In 2002, the first mesh device for transvaginal repair of POP was cleared for use as a class II moderate-risk device. About 1 in 8 women has surgery to repair POP over her lifetime, and a subset of these surgeries are completed transvaginally with the use of surgical mesh. Two manufacturers have been marketing three surgical mesh products for transvaginal repair of POP. In reviewing the PMAs submitted by the two manufacturers, the agency determined they failed to provide an adequate assessment of the long-term safety of these devices and failed to demonstrate an acceptable long-term benefit of these devices compared to transvaginal surgical tissue repair without the use of mesh, the agency said in a press statement. InARI signs MoU with NTTE Med University on translational research The present translational research in India will not be able to achieve its objectives unless important changes in education and training modules are addressed. The T1 (bench to bedside) and T2 (bedside to bench) phases of translational research are complementary and need important resources — mostly financial — that require quality collaborations between clinical and molecular scientists. It is important to note that in India, a lot of emphasis was given to develop physicianscientists (T2) and despite all the euphoria, innovations in the biomedical field have been negligible. The T1 cycle that exploits the expertise of research scientists outside medical institutes like universities and academic institutions has not been well integrated. It is extremely important to link molecular networks with clinical observations to complete the T1-T2 cycle. Especially in a country as big as ours with our low investment in research, more emphasis must be given to biomedical related problems where the scientific community works in tandem with clinicians. In this direction, the Institute for Applied Research and Innovation (InARI) and NITTE Medical University have joined hands by signing an MoU to create training, education and research programmes suitable for Indian healthcare needs. InARI focuses on applied research with direct benefits to the society and healthcare is its top priority. By signing this MoU with NITTE Medical University, a premier medical institute, a new chapter has begun in translational research for India Prof Dr Satheesh Kumar Bhandary (Vice Chancellor of NITTE Medical University), Dr Rajani Kanth Vangala (Founder and Managing Trustee of InARI), Dr Poornima V (co-founder and trustee – InARI), Dr Suchetha Kumari (Head of Research, NITTE Medical University) May 2019 / FUTURE MEDICINE / 11
Page 1: ₹ 250.00 VOL 6 | ISSUE 1 PAGES 10
Page 4 and 5: CASE REPORT MEDICAL PRACTICE PULMON
Page 6 and 7: EDUCATION CASE REPORT GENETICS OPHT
Page 8 and 9: news updates J&J donates 10,000 mor
Page 12 and 13: genetics ADVANCES IN MANAGING THALA
Page 14 and 15: column the catalyst Bridging the tr
Page 16 and 17: cover story UNLOCKING 16 / FUTURE M
Page 18 and 19: slug Rapidly-expanding suite of bio
Page 20 and 21: slug nonresponders in the magnitude
Page 22 and 23: irths change gut flora and increase
Page 24 and 25: protein), should help define which
Page 26 and 27: years. The CTS also recommends anti
Page 28 and 29: ASTHMA ALERT Asthma is increasing i
Page 30 and 31: pulmonology BRONCHIAL THERMOPLASTY
Page 32 and 33: drug approvals Hydrogel capsule for
Page 34 and 35: Olaparib to treat advanced breast c
Page 36 and 37: straight talk “WE STILL DON’T H
Page 38 and 39: that the allocation of the budget i
Page 40 and 41: case reports ROBOTIC BYPASS A uniqu
Page 42 and 43: case reports ECMO RESCUE Extracorpo
Page 44 and 45: case reports A AVOIDING AN AORTIC C
Page 46 and 47: case reports SILENT THALASSEMIA Alp
Page 48 and 49: column the cellview Future of thala
Page 50 and 51: medical practice VIOLENCE GOES VIRA
Page 52 and 53: esearch snippets Removal of damaged
Page 54 and 55: of 41 years was also involved in th
Page 56: hospital news Everstone to buy cont
Page 59 and 60: vast country with varied needs and
Page 61 and 62:
NGM2 NextGen Molecular Medicine NGM
Page 63 and 64:
located on the top face and both si
Page 65 and 66:
agents are available to help contro
Page 68 and 69:
AMRITA CENTRE FOR ROBOTIC SURGERY T
Page 70 and 71:
techniques, it would appear that th
Page 72 and 73:
guidelines URINARY INCONTINENCE 72
Page 74 and 75:
in bowel biofeedback and trans-anal
Page 76 and 77:
slug • the woman does not want bo
Page 78 and 79:
on medicines that may cause cogniti
Page 80 and 81:
mucus production and/or retention i
Page 82 and 83:
• pain • symptoms that are not
Page 84 and 85:
Ensure that the review includes a v
Page 86:
urinary, bowel and sexual dysfuncti
Page 89 and 90:
CUTTING-EDGE ADVANCES IN INTERVENTI
Page 91 and 92:
in India’ was loud and clear —
Page 94 and 95:
events Cahocon 2019 highlights need
Page 96 and 97:
calendar Upcoming conferences APR 2
Page 98 and 99:
UNDERSTAND THE FUTURE NOW AND APPLY
Page 100:
RNI Number KERENG/2012/44529
show all

may edition file

Create successful ePaper yourself

Delete template?

Save as template?